clinical trial · NCT04528082
Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease
Amgen·phase3·recruiting·n = 60
Behçet DiseaseApremilastPlacebo
brief summary
The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to \< 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.
started
Sep 9, 2021
primary completion
Feb 7, 2030
completion
Dec 17, 2030
last updated
Dec 1, 2025
official title
A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol